Evidence map›Paper›PMID 38547716›Full record

ArticleSchizophrenia research2024

Tobacco smoking and nicotine vaping in persons with first episode psychosis.

Melanie E Bennett, Deborah Medoff, Tovah Cowan, Lijuan Fang, Corinne Kacmarek, Maria Theodora Oikonomou, Monica E Calkins, Krista K Baker, Donna Bencivengo, Yasmine Boumaiz and 31 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Schizophrenia research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 11 institutions in 2 countries.

Melanie E BennettDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. Electronic address: mbennett@som.umaryland.edu.
Deborah MedoffDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Tovah CowanDepartment of Psychiatry, McGill University, Montreal, QC, Canada.
Lijuan FangDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Corinne KacmarekVA VISN5 Mental Illness Research, Education, and Clinical Center, Baltimore, MD, USA.
Maria Theodora OikonomouMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Monica E CalkinsPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Krista K BakerJohns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Donna BencivengoPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Yasmine BoumaizDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Robert W BuchananMaryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Phillip CampbellNeurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
K N Roy ChengappaDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Catherine G ConroyPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Akinyi CookeJohns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Fanghong DongPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Mandy FaubleUniversity of Pittsburgh Medical Center, Western Behavioral Health at Safe Harbor, Erie, PA, USA.
Richard W GoldbergDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Alexander HarvinDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
Megan B E JumperPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Belinda KauffmanDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Christian KellyUPMC, Western Psychiatric Hospital, Pittsburgh, PA, USA.
Christian G KohlerPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Julie KreyenbuhlDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Lan LiDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Alicia LuckstedDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Russell L MargolisDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jill A MarstellerDepartment of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Alex MoxamNeurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Denise NamowiczChildren's Services Center, Wilkes Barre, PA, USA.
Jamie OkoDepartment of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Jessie RiggsPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Arunadevi SaravanaDepartment of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA.
Deepak K SarpalDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; UPMC, Western Psychiatric Hospital, Pittsburgh, PA, USA.
Rachel ScheinbergDepartment of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
William R SmithNeurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Richard StatesUniversity of Pittsburgh Medical Center, Western Behavioral Health at Safe Harbor, Erie, PA, USA.
Jerome TaylorNeurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Child and Adolescent Psychiatry and Behavioral Sciences, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Crystal VatzaPennsylvania Early Intervention Center (PEIC)/HeadsUp, Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Neurodevelopment and Psychosis Section, Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Max WolcottJohns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Faith DickersonDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
University of Maryland, Baltimore · USUniversity of Pennsylvania · USJohns Hopkins Bayview Medical Center · USSheppard and Enoch Pratt Hospital · USJohns Hopkins University · USUniversity of Pittsburgh Medical Center · USChildren's Hospital of Philadelphia · USJohns Hopkins Medicine · USMcGill University · CAUniversity of Pittsburgh · USVA Capitol Health Care Network · US

Funding

UMB Admin CoreP01MH139228 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI MELANIE E. BENNETT, MONICA E CALKINS · 2024 to 2026
$6.3M
Improving Engagement in Black Clients Participating in Coordinated Specialty Care: A Mixed Methods Pilot StudyR01MH120550 · NIMH · UNIVERSITY OF MARYLAND BALTIMORE · PI BENNETT, MELANIE E. · 2020 to 2023
$5.9M
NIMH NIH HHS P01 MH139228NIMH NIH HHS R01 MH120550
6 · The paper itself

Abstract

Tobacco smoking is highly prevalent in persons with psychosis and is the leading cause of preventable mortality in this population. Less is known about tobacco smoking in persons with first episode psychosis (FEP) and there have been no estimates about the prevalence of nicotine vaping in FEP. This study reports rates of tobacco smoking and nicotine vaping in young people with FEP enrolled in Coordinated Specialty Care programs in Pennsylvania and Maryland. Using data collected from 2021 to 2023, we examined lifetime and recent smoking and vaping and compared smokers and vapers to nonusers on symptoms, functioning, and substance use. The sample included 445 participants aged 13-35 with recent psychosis onset. Assessments were collected by program staff. Overall, 28 % of participants engaged in either smoking or vaping within 30 days of the admission assessment. Smokers and vapers were disproportionately male, cannabis users, and had lower negative symptom severity than non-smokers. Vapers had higher role and social functioning. Both smoking and vaping were related to a longer time from psychosis onset to program enrollment. We compare these findings to previous studies and suggest steps for addressing smoking and vaping in this vulnerable population.

Indexed as

Psychotic DisordersVapingAdolescentAdultFemaleHumansMaleMarylandPennsylvaniaPrevalenceTobacco SmokingYoung AdultNicotineRecent onset psychosisSmokingTobaccoVaping

Identifiers

PMID38547716
PMCPMC11102839
OpenAlexW4393220908

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.